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Abstract
Introduction Because data on contrast-induced acute kidney
injury (CI-AKI) in pat ients undergoing cardiac
resynchronization therapy (CRT-D) are scarce, we aimed to
assess the incidence, natural course and prognostic importance
of this syndrome in CRT recipients.
Methods Study population consisted of 100 consecutive pa-
tients enrolled into the Triple Site Versus Standard Cardiac
Resynchronization (TRUSTCRT) trial, who were treatedwith
CRT-D. Two patients were excluded up to 3 months after
randomization and not analysed further. CI-AKI was defined
as a rise in serum creatinine of at least 26.5 μmol/L (0.3 mg/
dL) within 48 h after contrast exposure, or at least 50 %
increase from the baseline value during index hospital stay
with CRT-D implantation according to KDIGO Clinical Prac-
tice Guideline for Acute Kidney Injury.
Results Among 98 subjects of TRUST CRT trial, 10 patients
(10.2 %) developed CI-AKI after CRT-D implantation. In
patients with glomerular filtration rate (GFR) <60 mL/min/
1.73 m2 on admission, the incidence of CI-AKI was almost
twofold (15.4 %) higher than in subjects with GFR ≥60
(8.3 %). CRT-D recipients with CI-AKI had significantly
higher mortality rate (50.0 %) compared to those without
CI-AKI (17.0 %) during 30 months of follow-up (logrank
p=0.012). Multivariate Cox regression analysis showed
CI-AKI as significant and independent risk factor for
death in CRT-D recipients (hazard ratio 5.71; 95 % CI
5.16–6.26; p=0.001).
Conclusions Contrast-induced acute kidney injury is a serious
and frequent procedural complication of CRT-D implantation
with a significant negative influence on long-term survival.
The results suggest that clinical evaluation regarding renal
function should be considered in CRT-D recipients, both
before and after device implantation.
Keywords Cardiac resynchronization therapy . Chronic
kidney disease . Contrast-induced acute kidney injury . Heart
failure . Renal function
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Cardiac resynchronization therapy (CRT) has become the
standard of care for patients with symptomatic heart failure
(HF), significant electrical dyssynchrony and moderate to
severe left ventricular systolic dysfunction. Due to rapid prog-
ress in technology and broadening indications, CRT is being
employed more and more widely worldwide, with the esti-
mated implantation rate reaching 140 per million European
inhabitants in 2011 [1]. According to the current recommen-
dations, implantation of biventricular pacemaker should be
preceded by detailed intraoperative assessment of coronary
sinus anatomy, to allow further optimal selection of the target
vessel for left ventricular lead [2]. Although alternative imag-
ing techniques may be employed as well, balloon-occlusive
contrast angiography of the coronary sinus tributaries is
currently the gold standard. However, the use of contrast
media, even if non-ionic and low-osmotic, is inevitably asso-
ciated with the risk of contrast-induced acute kidney injury
(CI-AKI)—an iatrogenic syndrome with potentially serious
consequences demonstrated in some groups of patients [3–6].
Moreover, heart failure is one of the most important risk
factors of CI-AKI occurrence and therefore the evaluation of
this procedural complication seems to be especially important
in patients receiving CRT [5–8]. In fact, data limited to the
incidence of CI-AKI in a population of CRT-D recipients has
been so far reported in only two studies. However, according
to the authors’ best knowledge, there is a lack of data on CI-
AKI prognostic value in this set of patients [8, 9]. Therefore,
we aimed to assess the incidence, natural course and prognos-
tic importance of this syndrome in CRT recipients.
2 Methods
2.1 Patients
Study population consisted of patients enrolled into the Triple
Site Versus Standard Cardiac Resynchronization (TRUST
CRT) trial. TRUST CRT was a single-center, single-blind,
parallel, randomized, clinical trial to test the hypothesis that
triple-site (double-left single-right) pacing with defibrillator is
superior over conventional CRT with defibrillator [10, 11].
Eligibility criteria included heart failure in NYHA class III–IV
despite optimal pharmacotherapy, left ventricular ejection
fraction ≤35 %, QRS duration ≥120 ms and significant
(≥40 ms) intra- or interventricular mechanical dyssynchrony.
The primary end-point of the trial was the 6 months combined
response rate in both groups, the secondary end-point will
assess time to the first major adverse cardiac event after 3 years
[10].
Between 2008 and 2010, 100 consecutive patients whomet
the inclusion criteria were enrolled and randomized in a 1:1
fashion to triple-site or conventional CRT with defibrillator
(CRT-D). All patients were implanted with resynchronization
systems with implantable defibrillator-cardioverter (InSync
Sentry Model 7298, Medtronic, Minneapolis, USA). Stan-
dard, commercially available leads were used to pace/sense
the atrium, right ventricle and left ventricle. A bipolar Y-
connector (Lead Adaptor 2827, Medtronic) was employed to
connect in parallel two left ventricular leads in the triple-site
group. Atrioventricular and interventricular delays were opti-
mized between the first and the third postoperative day under
the echocardiographic guidance. Two patients were excluded
up to 3 months after randomization and data of these patients
were not analysed further.
The study protocol and procedural outcomes have been
published previously [10, 11]. The investigation conforms
with the principles outlined in the Declaration of Helsinki.
The protocol of the trial was approved by the locally
appointed ethics committee. Written informed consent has
been obtained from all study participants.
2.2 Procedural details
In order to analyse the potential association between postop-
erative renal function and characteristics of implantation pro-
cedure, data on procedural details were collected and
analysed. These included procedure duration (defined as
skin-to-skin time), fluoroscopy time and exposure, volume
of contrast medium used and final location of left ventricular
lead. Lead location was considered optimal, if its tip was in
non-apical, lateral or postero-lateral segment of the left ven-
tricle (as assessed in right- and left-lateral oblique fluoroscopic
projection). Iso-osmolar, non-ionic contrast medium
(Visipaque, GE Healthcare A.S., Norway) was used in all
patients to perform angiography of the coronary veins. Intra-
venous hydration with 0.9 % sodium chloride solution
(0.5 mL/kg per hour) was implemented before contrast expo-
sure and continued for 6–12 h in all patients with glomerular
filtration rate (GFR) <60. Metformin and potentially nephro-
toxic drugs, e.g. NSAIDs, aminoglycosides, were avoided or
discontinued for at least 48 h after contrast administration.
2.3 Follow-up and renal function assessment
Patients were followed 1 week, 1 month, 3 months and
6 months after randomization and every 6 months thereafter.
Apart from demographic, clinical data collection and echocar-
diographic measurements, serum creatinine levels were
assessed at baseline and 6 months after randomization. In all
patients, at least three blood samples were taken for serum
creatinine measurements at different time points during base-
line hospitalization: on admission, 1 day after implantation
and at discharge. Additional, daily measurements were col-
lected in cases of post-operative renal dysfunction, as needed.
One blood sample was taken for serum creatinine 6 months
after randomization. Serum creatinine levels were subsequent-
ly used to calculate GFR, according to the abbreviated Mod-
ification of Diet in Renal Disease Study Group Equation
proposed by National Kidney Foundation [12]. Baseline
chronic renal disease was defined as GFR <60 mL/min/
1.73 m2 on admission. CI-AKI was defined as a rise in serum
creatinine of at least 26.5 μmol/L (0.3 mg/dL) within 48 h
after contrast exposure, or at least 50 % increase from the
baseline value during index hospital stay with CRT-D implan-
tation according to KDIGO Clinical Practice Guideline for
Acute Kidney Injury [5, 6]. Response to CRTwas defined as a
reduction of at least one NYHA class after 6 months of
biventricular pacing.
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2.4 Major adverse events
Data on potential adverse events were collected throughout
the entire follow-up during scheduled and unscheduled visits,
via telephone calls, fax and other media from patients, rela-
tives, witnesses, death certificates, hospital records, outpatient
notes, letters, device memory and all other available sources.
This data was subsequently classified by two independent
members of Adverse Event Adjudication Board, blinded to
patients’ treatment arm. Major adverse cardiac event was
considered a composite of hospitalization for heart failure,
heart transplantation or all-cause death. Death certificates,
hospital records and device memory data were all used to
assess cardiac mortality either as sudden death or death from
coronary artery disease (CAD), including myocardial infarc-
tion, congestive heart failure, valvular heart disease, cardio-
myopathy, ventricular arrhythmia as well as other reasons of
cardiac arrest. Remote outcome was defined as total mortality
or any other endpoint occurrence within the whole 30-month
observation period.
2.5 Statistical analysis
Continuous parameters were expressed as medians with min-
imal andmaximal values; categorical variables were presented
as numbers and percentages. Comparative analysis between
groups was performed using Mann–Whitney U test for con-
tinuous variables and Chi-square or Fisher’s exact test, as
appropriate, for dichotomous parameters. Logrank tests were
used to compare Kaplan–Meier curves plotted for cumulative
survival. Independent predictors of death were identified with
multivariate Cox regression model and expressed as hazard
ratio with 95 % confidence interval. Regression models were
developed after the inclusion of all parameters with univariate
association with any-cause death and next backward stepwise
variable selection method was performed. Multivariate logis-
tic regression was used to identify independent predictors of
CI-AKI. Generalized linear models for binomial data were
constructed to test for interactions between treatment assign-
ment (conventional vs. triple-site CRT) and prognostic effect
of CI-AKI. All tests were double-sided. p value <0.05 was
considered statistically significant. All analyses were per-
formed using the software package Statistica (version 6.1,
StatSoft Inc., Tulsa, OK, USA).
3 Results
3.1 Incidence of CI-AKI among CRT-D recipients
Among 98 subjects of TRUST CRT Trial, 10 patients
(10.2 %) developed CI-AKI after CRT-D implantation. Addi-
tional analysis revealed that in patients with decreased GFR
<60 on admission the incidence of CI-AKI was almost two-
fold (15.4 %) higher than in subjects with GFR ≥60 (8.3 %).
3.2 Baseline and clinical characteristics of the study groups
Patients with CRT-D, who developed CI-AKI after implanta-
tion procedure, had very similar baseline and clinical charac-
teristics when compared to those who did not develop CI-AKI
(Table 1). In fact, the only significant baseline difference
between these two groups was serum creatinine level on
admission, which was higher in CI-AKI group. On the other
hand, both groups did not differ significantly with respect to
GFR on admission (Table 1). Considering data at discharge,
the CI-AKI group had significantly lower GFR and higher
prevalence of digoxin prescribed. All other baseline and in-
hospital parameters presented in the Table 1 were very similar
with non-significant differences between analysed groups.
Results of multivariate logistic regression analysis showed
that the only independent predictor of CI-AKI after CRT
implantation was a high serum creatinine concentration at
baseline (Table 2).
3.3 Natural course of CI-AKI
The analysis of natural course of renal function within partic-
ular study groups revealed that serum creatinine and median
GFR did not change significantly within 6 months after CRT-
D implantation (Fig. 1). The separate analysis of intergroup
differences showed that, similarly to the relation at discharge,
the median value of serum creatinine remained significantly
higher in CI-AKI group after 6 months of follow-up. The
median value of GFR after 6 months was lower in CI-AKI
group with a trend towards a significant difference (Table 1).
3.4 Prognostic value of CI-AKI
CRT-D recipients with CI-AKI had significantly higher mor-
tality rate (50.0 %) compared to those without CI-AKI
(17.0 %) during 30 months of follow-up (Table 1). Cumula-
tive surviving in analysed groups was presented with Kaplan–
Meier curves and their comparison with logrank test revealed
significant difference with p=0.012 (Fig. 2).
All the parameters with univariate association with death
and potential impact on mortality were incorporated into
multivariate Cox regression model. Selection of the risk fac-
tors for all-cause death adjustment is presented in footnotes of
Table 3. Multivariate Cox regression analysis using backward
stepwise variable selection method showed peak oxygen con-
sumption, QRS complex width, mitral effective regurgitant
orifice area and CI-AKI as significant and independent risk
factors for death in CRT-D recipients (Table 3). Prognostic
effect of CI-AKI on mortality (p for interactions=0.26), car-
diac mortality (p=0.09) and MACE (p=0.92) was
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Table 1 Clinical characteristics of the study population and comparative analysis among CRT-D recipients with respect to CI-AKI occurrence
A B C p value (B vs. C)
Overall population (n=98) CI-AKI (n=10) Without CI-AKI (n=88)
Baseline characteristics
Age—years 61 (39–82) 66 (57–76) 61 (39–82) 0.13
Male gender—no. (%) 77 (78.6) 9 (90.0) 68 (77.3) 0.36
Smoking—no. (%) 20 (20.4) 2 (20.0) 18 (20.5) 0.97
Paroxysmal atrial fibrillation—no. (%) 14 (14.3) 3 (30.0) 11 (12.5) 0.14
Arterial hypertension—no. (%) 62 (63.3) 7 (70.0) 55 (62.5) 0.65
Diabetes mellitus—no. (%) 34 (34.7) 4 (40.0) 30 (34.1) 0.71
Previous myocardial infarction—no. (%) 52 (53.1) 5 (50.0) 47 (53.4) 0.84
Prior CABG—no. (%) 12 (12.2) 3 (30.0) 9 (10.2) 0.07
Previous PCI—no. (%) 37 (37.8) 4 (40.0) 33 (37.5) 0.88
Ischaemic cardiomyopathy—no. (%) 60 (61.2) 6 (60.0) 54 (61.4) 0.93
NYHA class on admission 3 (3–4) 3 (3–4) 3 (3–4) 0.37
Left ventricle ejection fraction—% 24 (12–34) 23 (17–34) 24.0 (12–34) 0.25
LVESV—mL 192 (94–481) 198 (157–321) 189 (94–481) 0.39
LVEDV—mL 260 (120–586) 272 (199–393) 255 (120–586) 0.43
Mitral EROA—mm2 0 (0–48) 0 (0–36) 0 (0–48) 0.93
Right ventricle diameter—mm 31 (16–42) 29 (24–42) 31 (16–42) 0.87
RVSP—mmHg 39 (11–73) 38 (13–69) 39 (11–73) 0.94
QRS complex width—ms 168 (120–220) 174 (135–206) 168 (120–220) 0.73
6 MWD—m 346 (126–488) 316 (195–414) 346 (126–488) 0.26
Peak oxygen consumption—mL/kg/min 13.1 (7.1–21.0) 13.7 (8.5–15.5) 12.9 (7.1–21.0) 0.94
NT-proBNP on admission—pg/mL 1,627 (189–28,775) 2,581 (1,077–25,890) 1,506 (189–28,775) 0.09
C-reactive protein—mg/L 2.3 (0.3–105.2) 3.1 (0.3–28.6) 2.3 (0.4–105.2) 0.96
Complete revascularization—no. (%) 68 (69.4) 7 (70.0) 61 (69.3) 0.96
Triple Site CRT—no. (%) 48 (49.0) 5 (50.0) 43 (48.9) 0.95
Renal function parameters
Creatinine on admission—μmol/L 94 (48–285) 104 (86–180) 92 (48–285) 0.027
GFR on admission—mL/min/1.73 m2 72.7 (20.2–135.7) 65.6 (26.2–84.5) 73.8 (20.2–135.7) 0.08
Creatinine at discharge—μmol/L 138 (104–263) 138 (104–263) 85 (48–242) <0.001
GFR at discharge—mL/min/1.73 m2 74.6 (16.9–127.7) 46.9 (16.9–67.9) 80.7 (24.4–127.7) <0.001
Creatinine after 6 months—μmol/L 117 (71–243) 117 (71–243) 92 (52–198) 0.031
GFR after 6 months—mL/min/1.73 m2 73.4 (18.5–150.5) 56.8 (18.5–105.4) 75.1 (24.7–150.5) 0.059
Procedural details
Procedure duration: skin to skin—min 110 (55–225) 115 (75–165) 110 (55–225) 0.79
Fluoroscopy time—min 20.9 (4.5–112) 19.7 (10.3–39) 20.9 (4.5–112) 0.98
Contrast media volume—mL 40 (0–155) 37 (20–125) 40 (0–155) 0.79
Use of additional techniquea 24 (24.5) 3 (30.0) 21 (23.9) 0.67
Intraoperative decompensationb—no. (%) 7 (7.1) 0 (0.0) 7 (7.9) 0.35
Acute reoperationc—no. (%) 4 (4.1) 0 (0.0) 4 (4.5) 0.49
Optimal LV lead position—no. (%) 75 (76.5) 10 (100.0) 65 (73.9) 0.068
In-hospital-stay—days 4 (2–19) 3 (2–6) 4 (2–19) 0.11
Medication and pacing burden
Beta-adrenergic blocker—no. (%) 97 (99.0) 10 (100) 87 (98.9) 0.74
ACE-inhibitor/ARB—no. (%) 97 (99.0) 10 (100) 87 (98.9) 0.74
Spironolactone/eplerenon—no. (%) 94 (95.9) 9 (90.0) 85 (96.6) 0.32
Loop diuretics—no. (%) 91 (92.9) 9 (90.0) 82 (93.2) 0.71
Digoxin—no. (%) 10 (10.2) 3 (30.0) 7 (8.0) 0.032
Statin—no. (%) 78 (79.6) 10 (100) 68 (77.3) 0.095
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independent from the treatment arm (conventional vs. triple-
site CRT).
4 Discussion
The main finding of the present study is that contrast-induced
acute kidney injury is a frequent complication of CRT-D im-
plantation and has a significant negative influence on long-term
survival. As it has been previously described, contrast-induced
acute kidney injury, named also contrast-induced nephropathy
(CIN), was a serious procedural complication with significant
impact on long-term prognosis in subjects undergoing percuta-
neous cardiovascular procedures [5]. It has been especially well
characterized in the population of patients who underwent
percutaneous coronary intervention (PCI) or coronary angiog-
raphy and was associated with a significant worsening of
prognosis in this set of subjects [4–6, 13, 14]. Very limited data
is however available on the incidence of contrast-induced acute
kidney injury in the population of CRT-D recipients, and ac-
cording to the authors’ best knowledge, there is no data on its
prognostic value in this set of patients [8, 9].
The CI-AKI incidence of 10.2 % in our study is similar to
the findings reported by other authors. Actually, there have
been so far only two studies in which the frequency of CI-AKI
has been assessed [8, 9]. Cowburn et al. demonstrated 14 %
occurrence of contrast-induced nephropathy defined as at least
25 % increase in serum creatinine from the baseline within
48 h after contrast exposure during CRT implantation [8].
More recently, Tester et al. revealed 8 % incidence of
contrast-induced nephropathy after CRT therapy implanta-
tion; however, the authors used a different definition of con-
trast nephropathy, which was a rise in serum creatinine of at
least 25 % from the baseline ≥48 h after contrast exposure [9].
High frequency of contrast-induced nephropathy in the study
of Cowburn et al. might be the result of both less common use
of iso-osmolar, non-ionic contrast media and higher volumes
of contrast as well as worse baseline renal function parameters
Table 1 (continued)
A B C p value (B vs. C)
Overall population (n=98) CI-AKI (n=10) Without CI-AKI (n=88)
Amiodarone—no. (%) 6 (6.1) 1 (10.0) 5 (5.7) 0.59
Percentage of CRT pacing—% 99.7 (66.0–100) 99.6 (82.8–100) 99.7 (66.0–100) 0.58
Outcomes
Responders to CRT—no. (%) 86 (87.7) 10 (100) 76 (86.4) 0.21
1-year hospitalization for HF—no. (%) 19 (19.4) 4 (40.0) 15 (17.0) 0.083
1-year MACE—no. (%) 21 (21.4) 4 (40.0) 17 (19.3) 0.13
1-year mortality—no. (%) 4 (4.1) 1 (10.0) 3 (3.4) 0.32
Remote hospitalization for HF—no. (%) 33 (33.7) 4 (40.0) 29 (33.0) 0.66
Remote MACE—no. (%) 34 (34.7) 6 (60.0) 28 (31.8) 0.079
Remote mortality—no. (%) 20 (20.4) 5 (50.0) 15 (17.0) 0.016
Cardiac mortality—no. (%) 14 (14.3) 4 (40.0) 10 (11.4) 0.016
Sudden deaths—no. (%) 4 (4.1) 2 (20.0) 2 (2.3) 0.007
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, CABG coronary artery by-pass grafting, CI-AKI contrast-induced acute kidney
injury, CRT cardiac resynchronization therapy, EROA effective regurgitant orifice area,HF heart failure,GFR glomerular filtration rate, LV left ventricle,
LVEDV left ventricle end-diastolic volume, LVESV left ventricle end-systolic volume, MACE major adverse cardiac event, 6 MWD 6-min walking
distance,NT-proBNPN-terminal prohormone of brain natriuretic peptide, PCI percutaneous coronary intervention, RVSP right ventricle systolic pressure
Values presented as median with minimum and maximum or percentage of subjects
a Angioplasty or stenting within coronary vein (3 patients), use of active fixation lead (21 patients) or use of sub-selective catheters (7 patients)
b Requiring transient intravenous inotropic support
cWithin the same hospital stay, due to lead dislocation (three patients) or phrenic nerve stimulation (one patient)
Table 2 Predictors of contrast-induced acute kidney injury after CRT
implantation
Variable Odds ratio (95 % CI) p value






QRS complex width > median value
[>164 ms]
1.15 (0.27–4.90) 0.85
Left ventricle ejection fraction >
median value [>24 %]
0.30 (0.06–1.59) 0.15
Serum creatinine level > median
value [>94 μmol/L]
6.23 (1.19–32.6) 0.03
CI confidence interval, CRT cardiac resynchronization therapy
J Interv Card Electrophysiol (2014) 40:1–8 5
[8]. For comparison, the incidence of contrast-induced acute
kidney injury after PCI ranges from 2.0 % to even 20–30 %
with respect to co-morbidities, and mainly depends on the
baseline, pre-procedural renal dysfunction, which is one of the
most important risk factors of CI-AKI development [4–7, 13,
14]. According to CIN Consensus Working Panel from 2006,
contrast-induced nephropathy is responsible for approximate-
ly 11 % of hospital-acquired renal failure cases [13]. Thus,
these findings coming mainly from registries, where coronary
angiograms and PCI were the leading causes of CIN, are
similar to the incidence of CI-AKI demonstrated in CRT
recipients. Of course, the contrast volumes used during PCI
are much higher than during CRT-D implantation. However,
on the other hand, patients with chronic heart failure do have
very often concomitant chronic kidney disease and thus are at
increased risk of CI-AKI development despite relatively small
amounts of contrast medium used during the procedure. Two-
fold increase of the incidence of CI-AKI in patients with GFR
Table 3 Independent predictors of death in CRT-D recipients




QRS complex width [1 ms increase] 0.97 (0.96–0.98) 0.005
Mitral EROA [1 mm2 increase] 1.06 (1.05–1.07) <0.001
Contrast-induced acute kidney injury 5.71 (5.16–6.26) 0.001
Adjusted for the following: previous percutaneous coronary intervention,
NYHA class on admission, NT-proBNP on admission, QRS complex
width, mitral EROA, baseline peak oxygen consumption, digoxin at
discharge, glomerular filtration rate at discharge, contrast-induced acute
kidney injury
CI confidence interval, EROA effective regurgitant orifice area
Fig. 1 Changes in renal function estimated with serum creatinine (a) and
glomerular filtration rate (b) in CRT-D recipients with respect to CI-AKI
occurrence.CI-AKI = contrast-induced acute kidney injury;CRT-D = cardiac
resynchronization therapy defibrillator;FU= follow-up;NS= non-significant
Fig. 2 Kaplan–Meier curves for
cumulative survival in CRT-D
recipients with respect to CI-AKI
occurrence. CI-AKI = contrast-
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<60 on admission, demonstrated in the present study, is con-
sistent with previous observations on increasing risk of
contrast-induced nephropathy with declining baseline renal
function in the population of PCI patients [15]. It has been
stated that one of the most important risk factors of CI-AKI is
preexisting chronic kidney disease [5, 7, 15].
Despite very similar baseline clinical characteristics of
CRT-D patients, those with CI-AKI had significantly worse
long-term survival than subjects without CI-AKI. Moreover,
taking into account cardiac mortality, the significant difference
was also observed. The aforementioned two studies on
contrast-induced nephropathy after CRT presented data on
the incidence of CI-AKI, however without the outcome anal-
ysis [8, 9]. Tester et al. mentioned only that the authors ob-
served a trend towards higher long-term mortality associated
with development of CIN [9]. To the authors’ best knowledge,
there is currently no other data in the literature on the outcome
of CRT patients with CI-AKI. It is also worth noting that after
1 year the difference in mortality, though statistically non-
significant, was considerably high (10 vs. 3.4 %) with its
further progression within next months. A very high 30-
month mortality in CI-AKI group, almost threefold higher than
in patients without CI-AKI, suggests that a very detailed clin-
ical evaluation regarding renal function should be considered
in this set of patients, both before and after CRT implantation,
with implementation of all clinically proven preventive strate-
gies against CI-AKI. Very high mortality rates in CRT-D
recipients, who developed CI-AKI, might be the result of an
interaction of many clinical and biological factors such as
follows: predisposition to fluid overload leading to higher rates
of hospitalization due to heart failure, proneness to electrolyte
disturbances that may lead to arrhythmic events and sudden
deaths, natural course of renal failure with its all biological
consequences like abnormal vascular biology and endothelial
dysfunction, hyperactivation of the renin-angiotensin system,
anemia, changes in lipids, and disturbances in coagulation.
Similarly to our findings, high mortality rates in the group of
CI-AKI patients were also observed by Lin et al. in CRT
recipients with GFR≤60 during 3 years of follow-up [16]. Some
other studies have also demonstrated that renal dysfunction is an
important predictor of reduced both survival and left ventricle
function improvement following CRT [17–21]. The potential
confirmation of this phenomenon might be sustained compro-
mised renal function in CI-AKI group after 6 months of follow-
up. Moreover, the fact that serum creatinine and median GFR
did not change significantly within 6 months in particular study
groups supports the hypothesis that CRT-D may have a limited
impact on delaying or preventing deterioration of renal function.
We also observed that contrast exposure is a trigger for
some patients with asymptomatic renal failure. Thus, CI-AKI
could be a marker of patients with predisposition to overt renal
failure, similarly to prediabetic states, which predispose to
overt diabetes mellitus.
Another important and not reported previously finding of
the present study is that CI-AKI is the strongest independent
risk factor of any-cause death in CRT-D recipients, regardless
of the GFR value at discharge. Other independent risk factors
such as mitral regurgitation, QRS complex width and peak
oxygen consumption are well-established risk predictors dem-
onstrated in previously published studies [1, 2, 22–28]. The
phenomenon of risk reduction with increasing QRS duration
revealed in our study is in line with preceding reports and is
explained by a high probability of substantial benefit from CRT
therapy observed in CRT recipients with wider baseline QRS
complex [22, 23]. The results of multivariate regression analy-
sis with adjustment to GFR at discharge and digoxin usage—
the only two differences between study groups, confirmed the
finding that CI-AKI had significant impact on long-term prog-
nosis in CRT-D recipients independent of other confounders.
This observation is additionally supported by very similar
baseline and clinical characteristics of both study groups.
4.1 Study limitations
One of the potential limitations of the study is relatively small
study population, which could have potentially biased the re-
sults. On the other hand, this single-centre randomized study
encompassed consecutive heart failure patients, who were treat-
ed similarly both invasively (CRT-D implantation) and medical-
ly, and this fact makes the study population very homogenous
and strengthens the results. The sub-analysis of data from the
TRUST CRT trial, which was not primarily designed for the
evaluation of CI-AKI in patients undergoing cardiac
resynchronization therapy, may also bias the results. Another
limitation of the study is lack of complete data from post-
mortemCRT-D interrogation. Therefore, not all causes of deaths
were clear, especially the sudden ones. These data would be
helpful in explaining the potential reasons for different long-term
prognosis and very high mortality rates in patients with CI-AKI.
In conclusion, CI-AKI is a serious and frequent procedural
complication of CRT-D implantation with a significant nega-
tive influence on long-term survival independent of other risk
factors. The results of the present study should be confirmed
in the large cohort studies but they suggest that detailed
clinical evaluation regarding renal function should be consid-
ered in CRT recipients, both before and after device implan-
tation, with implementation of all clinically proven
nephroprotective strategies.
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